Issam Zineh has joined the US Food and Drug Administration as associate director for genomics in the Office of Clinical Pharmacology.
Zineh was previously associate director of the Pharmacogenomics Center at the University of Florida, where he was also an assistant professor of clinical practice.
Zineh replaces Felix Frueh, who left the FDA earlier this year to join Medco Health Solutions as VP of research and development for personalized medicine.
Phyllis Whiteley and Dan Riskin have joined venture capital firm Mohr Davidow Ventures as executive-in-residence and entrepreneur-in-residence, respectively.
Whiteley most recently worked with 5AM Ventures, where she co-founded Anaphore. Prior to that, she was an officer and senior vice president at Perlegen Sciences, VP of strategic portfolio management for F. Hoffman La Roche, and a senior research immunologist at Merck.
Riskin was the president of Interventional Dynamics, a medical technology R&D firm. Before that, he was in business development at Roche Diagnostics, where he worked with MIT Media Lab and BodyMedia to commercialize an IT-based obesity management system.
Riskin holds an MBA with a focus in bioinformatics from MIT Sloan School of Management.
The National Science Foundation is accepting nominations for the 2009 National Medal of Science through December 5, 2008.